Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 9/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.75 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.75 |
| ▸ | PTGES | O14684 | 1/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.75 |
| ▸ | POLL | Q9UGP5 | 7/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Garcinol SCHEMBL29395703 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL4607088 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL31345886 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL19565392 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23815758 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23815733 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23607580 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23815760 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Garcinol SCHEMBL294532 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Xanthochymol SCHEMBL294395 | 0.92 | EP300 (0.63) | EP300HDAC11KAT2BPTGESHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | EP300 1842/4885HDAC11 1735/4885KAT2B 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.